Drugs / Rubidium-82
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02003456 | Dec 2013 → Aug 2014 | myocardial infarction, myocardial ischemia | University of Michigan | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01379677 | Feb 2011 → Nov 2013 | coronary artery disorder | Advanced Accelerator Applications | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05286593 | Dec 2021 → Sep 2022 | coronary artery disorder, myocardial infarction | Ochsner Health System | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06965621 Comparator | Nov 2025 → Oct 2026 expected | cardiomyopathy, heart failure | Innervate Radiopharmaceuticals LLC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rubidium-82 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05286593 ↗ |
| Modality | Diagnostic / imaging agent | “PET Radiopharmaceutical to assess myocardial perfusion” NCT06965621 ↗ |
| Route | Intravenous | “Intravenous Use” NCT01379677 ↗ |